More on Novartis Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth Novartis Q1 2026 Earnings Preview Novartis pulls bid to expand Pluvicto label for prostate cancer in EU
More on Novartis Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth Novartis Q1 2026 Earnings Preview Novartis pulls bid to expand Pluvicto label for prostate cancer in EU
Matveev_Aleksandr/iStock via Getty Images Investor sentiment towards Velo3D, Inc.'s ( VELO ) business has surged in recent months, driven by expectations of a growth acceleration and a transition to profitability. Much of this optimism stems from Velo3D's high-profile customers, like SpaceX. Velo3D's shift towards a service model (Rapid Production Solutions) is also expected to create stronger gro...
Matveev_Aleksandr/iStock via Getty Images Investor sentiment towards Velo3D, Inc.'s ( VELO ) business has surged in recent months, driven by expectations of a growth acceleration and a transition to profitability. Much of this optimism stems from Velo3D's high-profile customers, like SpaceX. Velo3D's shift towards a service model (Rapid Production Solutions) is also expected to create stronger growth and margins. I tend to think that this is the better way of monetizing additive manufacturing technology, particularly when targeting high-value use cases, as Velo3D will be able to capture more of the value that it creates. The service model should also appeal to customers who are reluctant to make a significant investment in hardware. Guidance is dependent on this transition working, though, and Velo3D will need to make substantial capital investments in the coming years. I previously suggested that Velo3D had no room for error due to its weak balance sheet and ongoing losses. Aside from this, I have always felt that the company has had interesting technology that could form the basis of a solid business. Somewhat surprisingly, this hasn't translated into meaningful commercial success so far, though. While macro conditions have been challenging in recent years, Velo3D's focus on aerospace and defense should have limited the impact of this, suggesting company-specific issues. Bankruptcy risk and reliability concerns appear to have prevented some customers from scaling in the past, although this should now be less of a concern. As a result, it is reasonable to expect stronger growth going forward. Despite this, I am not convinced that Velo3D has enough differentiation to create a strong business or that its niche solution provides a large enough end market to create strong returns for investors. Market Conditions Velo3D has always had a focus on space, defense, and aerospace due largely to the ability of its technology to produce metal parts with complex internal geomet...
(RTTNews) - Asian stocks ended mostly lower on Tuesday as U.S.-Iran talks remained at a standstill and investors braced for the earnings releases of the Magnificent Seven companies this week.
(RTTNews) - Asian stocks ended mostly lower on Tuesday as U.S.-Iran talks remained at a standstill and investors braced for the earnings releases of the Magnificent Seven companies this week.
Audias Flores, known as ‘El Jardinero’, of the Jalisco New Generation Cartel, captured in western state of Nayarit Mexican special forces have arrested one of the top commanders of the powerful Jalisco New Generation Cartel in the western state of Nayarit. Audias Flores, known as “El Jardinero”, is a regional commander in control of swathes of CJNG territory along Mexico’s Pacific coast. He was co...
Audias Flores, known as ‘El Jardinero’, of the Jalisco New Generation Cartel, captured in western state of Nayarit Mexican special forces have arrested one of the top commanders of the powerful Jalisco New Generation Cartel in the western state of Nayarit. Audias Flores, known as “El Jardinero”, is a regional commander in control of swathes of CJNG territory along Mexico’s Pacific coast. He was considered a potential successor to Nemesio Oseguera, alias “El Mencho”, who ran the cartel and was killed in a security operation in February . Continue reading...
The Board of Director of Tivoli A/S has adopted the Interim Report for the period 1 January – 31 March 2026 on 28 April 2026. Tivoli opened the summer season on 27 March, slightly earlier than last year, where the season opened on 4 April. This impacts, as expected, the result for the period, as outlined:
The Board of Director of Tivoli A/S has adopted the Interim Report for the period 1 January – 31 March 2026 on 28 April 2026. Tivoli opened the summer season on 27 March, slightly earlier than last year, where the season opened on 4 April. This impacts, as expected, the result for the period, as outlined:
Bestyrelsen for Tivoli A/S har den 28. april 2026 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2026. Tivoli åbnede sommersæsonen 27. marts, hvilket er lidt tidligere end sidste år hvor sæsonen åbnede 4. april. Dette påvirker, som forventet, resultatet for perioden som i hovedtræk er:
Bestyrelsen for Tivoli A/S har den 28. april 2026 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2026. Tivoli åbnede sommersæsonen 27. marts, hvilket er lidt tidligere end sidste år hvor sæsonen åbnede 4. april. Dette påvirker, som forventet, resultatet for perioden som i hovedtræk er:
Cnooc Ltd. reported stronger profit in the first quarter, as China’s top offshore driller benefited from rising global crude prices from the war in the Middle East. Net income rose to 39.14 billion yuan ($5.7 billion) in the first three months through March from 36.6 billion yuan in the same period a year earlier, the company said in an exchange filing on Tuesday. Global benchmark Brent oil jumped...
Cnooc Ltd. reported stronger profit in the first quarter, as China’s top offshore driller benefited from rising global crude prices from the war in the Middle East. Net income rose to 39.14 billion yuan ($5.7 billion) in the first three months through March from 36.6 billion yuan in the same period a year earlier, the company said in an exchange filing on Tuesday. Global benchmark Brent oil jumped to as high as almost $120 a barrel in March, and averaged around $78 over the quarter, higher than the same period last year. The conflict has flipped market expectations from oversupply to a tighter oil balance for 2026, offering strong support to upstream producers. The offshore giant, the main contributor to growth in China’s domestic oil supply, has been ramping up upstream development over the past decade. Cnooc’s output rose by 8.6% to 205.1 million barrels of oil equivalent during the quarter, broadly in line with the company’s goal to maintain elevated production through 2030, part of Beijing’s efforts to improve energy security. Cnooc said its capital expenditures were 33 billion yuan for the quarter, up 19% from the same period last year, as it accelerated its capacity construction. The company said earlier it planned to keep capital spending broadly stable at levels similar to last year, prioritizing investment to sustain production growth. The firm is more sensitive to oil price swings than its state-owned peers, given its limited downstream refining and marketing operations. “Geopolitical tensions in the Middle East exacerbated inflation risks, but China’s economy got off to a strong and good start,” the company said in an exchange filing.
[The content of this article has been produced by our advertising partner.] Amid ongoing geopolitical tensions and fractured international relations, the University of Hong Kong (HKU) has launched a new School of Governance and Policy (SGP) that aims to foster dialogue and train a new generation of policymakers. The interdisciplinary school stands out by convening a powerful convergence of global ...
[The content of this article has been produced by our advertising partner.] Amid ongoing geopolitical tensions and fractured international relations, the University of Hong Kong (HKU) has launched a new School of Governance and Policy (SGP) that aims to foster dialogue and train a new generation of policymakers. The interdisciplinary school stands out by convening a powerful convergence of global intellectual leadership and cross-disciplinary expertise. By integrating the strengths of the Social...
hapabapa AstraZeneca’s ( AZN ) fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the U.S. for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older, the company said on Tuesday. Breztri is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic anta...
hapabapa AstraZeneca’s ( AZN ) fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the U.S. for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older, the company said on Tuesday. Breztri is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic antagonist. Breztri (320/18/9.6μg) was approved in the U.S. in 2020 to treat adults with chronic obstructive pulmonary disease and was prescribed to more than 6.8 million patients globally in 2025. “Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms," Njira Lugogo from the Department of Internal Medicine, University of Michigan, said. "The FDA approval of Breztri as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner.” More on AstraZeneca PLC AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns AstraZeneca: The Big China Bet AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy Astra to seek accelerated nod for Ultomiris in IgA nephropathy after positive late-stage data Astra posts another late-stage trial win for COPD therapy